CN110691773B - 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 - Google Patents

作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 Download PDF

Info

Publication number
CN110691773B
CN110691773B CN201880033697.9A CN201880033697A CN110691773B CN 110691773 B CN110691773 B CN 110691773B CN 201880033697 A CN201880033697 A CN 201880033697A CN 110691773 B CN110691773 B CN 110691773B
Authority
CN
China
Prior art keywords
mmol
compound
mixture
synthesis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880033697.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110691773A (zh
Inventor
J-F.邦凡蒂
B.R.R.凯斯特莱恩
D.A.M-E.巴迪奥
A.D.M.马尔尚
E.科塞曼斯
J.M.C.福尔坦
G.J.M.梅塞
P.J-M.B.拉布瓦松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Janssen Pharmaceuticals Inc
Original Assignee
Katholieke Universiteit Leuven
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven, Janssen Pharmaceuticals Inc filed Critical Katholieke Universiteit Leuven
Publication of CN110691773A publication Critical patent/CN110691773A/zh
Application granted granted Critical
Publication of CN110691773B publication Critical patent/CN110691773B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880033697.9A 2017-05-22 2018-05-18 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物 Active CN110691773B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172237.4 2017-05-22
EP17172237 2017-05-22
PCT/EP2018/063028 WO2018215315A1 (en) 2017-05-22 2018-05-18 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (2)

Publication Number Publication Date
CN110691773A CN110691773A (zh) 2020-01-14
CN110691773B true CN110691773B (zh) 2023-06-23

Family

ID=58745157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033697.9A Active CN110691773B (zh) 2017-05-22 2018-05-18 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物

Country Status (25)

Country Link
US (2) US11407715B2 (https=)
EP (1) EP3630723B1 (https=)
JP (1) JP7203764B2 (https=)
KR (1) KR102625988B1 (https=)
CN (1) CN110691773B (https=)
AR (1) AR111878A1 (https=)
AU (1) AU2018274100B2 (https=)
BR (1) BR112019024195A2 (https=)
CA (1) CA3060583C (https=)
CL (1) CL2019003294A1 (https=)
CO (1) CO2019012035A2 (https=)
CR (1) CR20190530A (https=)
EA (1) EA201992782A1 (https=)
EC (1) ECSP19083640A (https=)
ES (1) ES2929667T3 (https=)
IL (1) IL270726B2 (https=)
MA (1) MA48943A (https=)
MX (1) MX393586B (https=)
NI (1) NI201900119A (https=)
PE (1) PE20200604A1 (https=)
PH (1) PH12019502559A1 (https=)
TW (1) TWI758480B (https=)
UA (1) UA125407C2 (https=)
UY (1) UY37742A (https=)
WO (1) WO2018215315A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
PE20260044A1 (es) * 2023-06-05 2026-01-09 Zydus Lifesciences Ltd Compuestos novedosos para tratar infecciones virales
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024223A (zh) * 2011-09-26 2014-09-03 鲁汶天主教大学 病毒复制抑制剂
WO2016050841A1 (en) * 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241178T3 (es) 1997-10-27 2005-10-16 Eli Lilly And Company Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2.
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
ZA200705872B (en) 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
JP2008530124A (ja) 2005-02-09 2008-08-07 ミジェニックス インコーポレイテッド フラビウイルス感染症を処置または予防するための組成物および方法
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
JP5559174B2 (ja) * 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷感−メントール受容体拮抗剤
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US7948798B1 (en) 2009-07-22 2011-05-24 Marvell International Ltd. Mixed multi-level cell and single level cell storage device
CA2785563C (en) 2010-01-15 2019-05-14 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
EP2624519A4 (en) * 2011-09-30 2014-04-23 Huawei Tech Co Ltd NETWORKING METHOD AND DEVICE
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
CN116987080A (zh) 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
ME03344B (me) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supstituisani indoli kao inнibitori replikacije denga virusa
NO2721243T3 (https=) 2014-10-01 2018-10-20
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX374683B (es) 2015-11-03 2025-03-04 Zoetis Services Llc Compuestos polimericos sol-gel y sus usos.
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
ES2804580T3 (es) 2016-03-31 2021-02-08 Takeda Pharmaceuticals Co Compuesto heterocíclico
MX2018011788A (es) * 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MY210545A (en) 2016-04-01 2025-09-30 Kite Pharma Inc Chimeric receptors to flt3 and methods of use thereof
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
EP3436457B1 (en) 2016-04-01 2022-07-20 Basf Se Bicyclic compounds
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR20200068750A (ko) 2016-04-01 2020-06-15 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
AU2017241837B2 (en) 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024223A (zh) * 2011-09-26 2014-09-03 鲁汶天主教大学 病毒复制抑制剂
WO2016050841A1 (en) * 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
US11407715B2 (en) 2022-08-09
IL270726A (en) 2020-01-30
KR20200009027A (ko) 2020-01-29
UA125407C2 (uk) 2022-03-02
EA201992782A1 (ru) 2020-03-24
CA3060583A1 (en) 2018-11-29
EP3630723A1 (en) 2020-04-08
US20220340522A1 (en) 2022-10-27
CA3060583C (en) 2024-06-04
US11795149B2 (en) 2023-10-24
TWI758480B (zh) 2022-03-21
AR111878A1 (es) 2019-08-28
EP3630723B1 (en) 2022-08-24
ES2929667T3 (es) 2022-11-30
NI201900119A (es) 2020-03-23
CR20190530A (es) 2020-01-24
BR112019024195A2 (pt) 2020-06-23
UY37742A (es) 2018-11-30
KR102625988B1 (ko) 2024-01-16
WO2018215315A1 (en) 2018-11-29
ECSP19083640A (es) 2019-11-30
PH12019502559A1 (en) 2021-01-25
CL2019003294A1 (es) 2020-03-20
MX2019013893A (es) 2020-01-20
MX393586B (es) 2025-03-24
PE20200604A1 (es) 2020-03-10
JP7203764B2 (ja) 2023-01-13
IL270726B2 (en) 2023-05-01
CN110691773A (zh) 2020-01-14
CO2019012035A2 (es) 2020-01-17
AU2018274100B2 (en) 2022-06-23
AU2018274100A1 (en) 2019-11-21
TW201908291A (zh) 2019-03-01
JP2020520946A (ja) 2020-07-16
US20200255376A1 (en) 2020-08-13
MA48943A (fr) 2021-04-28
IL270726B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
CN110691773B (zh) 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
JP7132399B2 (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
CN110612284B (zh) 作为登革热病毒复制抑制剂的经取代的二氢吲哚衍生物
CN108368044B (zh) 作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物
CN109195949B (zh) 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
CN108884033B (zh) 作为登革病毒复制抑制剂的经取代的吲哚衍生物
TWI771420B (zh) 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物（一）
EA020815B1 (ru) Ингибиторы вируса гепатита с
TW201708227A (zh) Ｒｓｖ抗病毒吡唑並-以及三唑並-嘧啶化合物
KR20170063802A (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
JP2019510034A (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
KR20170103820A (ko) 뎅기 바이러스 복제 억제제로서의 인돌 유도체
CN117062804A (zh) 1,3-取代的环丁基衍生物及其用途
HK40023943B (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK40023943A (en) Substituted indoline derivatives as dengue viral replication inhibitors
OA19488A (en) Substituted indoline derivatives as dengue viral replication inhibitors.
EA041349B1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
HK1260478A1 (en) Substituted indole compound derivatives as dengue viral replication inhibitors
HK1260482A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant